Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

Reviva Pharmaceuticals logo
$0.53 -0.03 (-5.94%)
Closing price 04:00 PM Eastern
Extended Trading
$0.53 0.00 (0.00%)
As of 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Key Stats

Today's Range
$0.49
$0.55
50-Day Range
$0.56
$2.08
52-Week Range
$0.50
$4.28
Volume
845,106 shs
Average Volume
1.10 million shs
Market Capitalization
$17.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Remove Ads

Reviva Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

RVPH MarketRank™: 

Reviva Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 195th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Reviva Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Reviva Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.97) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Reviva Pharmaceuticals is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Reviva Pharmaceuticals is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Reviva Pharmaceuticals has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Reviva Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.70% of the float of Reviva Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently decreased by 24.80%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Reviva Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Reviva Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.70% of the float of Reviva Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently decreased by 24.80%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Reviva Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    9 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.18% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Reviva Pharmaceuticals' insider trading history.
Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVPH Stock News Headlines

Caught on Camera: Elon Musk’s “Area 51”
You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see this footage.) A lot of people believe the U.S. government is hiding aliens at the highly classified U.S. Air Force facility in Nevada known as “Area 51.”
Unusually active option classes on open February 12th
See More Headlines

RVPH Stock Analysis - Frequently Asked Questions

Reviva Pharmaceuticals' stock was trading at $1.81 at the beginning of 2025. Since then, RVPH shares have decreased by 70.7% and is now trading at $0.53.
View the best growth stocks for 2025 here
.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its earnings results on Monday, March, 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07.

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Salesforce (CRM), Adobe (ADBE), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Airbnb (ABNB) and Marvell Technology (MRVL).

Company Calendar

Last Earnings
3/31/2025
Today
4/04/2025
Next Earnings (Estimated)
4/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RVPH
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$17.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+1,786.8%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-39,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.20 per share
Price / Book
2.65

Miscellaneous

Free Float
24,352,000
Market Cap
$17.72 million
Optionable
Optionable
Beta
-0.09
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:RVPH) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners